Institutional members access full text with Ovid®

Share this article on:

Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms

Yalamanchili, Vinod MBBS; Gallagher, J. Christopher MD

doi: 10.1097/gme.0b013e31823bcec5
Original Articles

Objective The aim of this study was to examine the effect of hormone therapy and calcitriol on depression in older postmenopausal women and to determine whether the response was associated with polymorphisms of estrogen receptor α and vitamin D receptor.

Methods In a double-blind placebo-controlled prospective trial involving 489 postmenopausal older women, a secondary analysis of depression was done. The Geriatric Depression Scale was used to screen for depression. We used binary logistic regression to examine the effect of treatment on depression and one-way analysis of variance to find a relationship between gene polymorphisms and depression.

Results There was no effect of hormone therapy (odds ratio [OR], 1.65; 95% CI, 0.66-4.12; P = 0.277), calcitriol (OR, 1.15; 95% CI, 0.43-3.11; P = 0.772), or hormone therapy with calcitriol (OR, 1.01; 95% CI, 0.36-2.80; P = 0.979) on depression. Neither the polymorphisms of estrogen receptor α (XbaI-β = 0.093; CI, −0.337 to 1.350; P = 0.239 and PvuII-β = −0.064; CI, −1.171 to 0.491, P = 0.421) nor those of vitamin D receptor (BsmI-β = 0.044, CI −2.546 to 3.030, P = 0.865 and TaqI-β = −0.015, CI −2.900 to 2.738, P = 0.955) were associated with depression.

Conclusion In older postmenopausal women, there was no effect of hormone therapy and calcitriol either individually or in combination with depression. Estrogen receptor α and vitamin D receptor polymorphisms are not associated with depression or the response to intervention in older postmenopausal women. Additional trials are required to confirm these findings.

From the Bone Metabolism Unit, Creighton University School of Medicine, Omaha, NE.

Received August 19, 2011; revised and accepted October 6, 2011.

Funding/support: This study was supported by National Institutes of Health funds (Grants U01-AG10373 and AG10358).

Financial disclosure/conflicts of interest: J.C.G. has received consulting fees and honoraria from Wyeth-Pfizer and Roche. He has also served on the Advisory Council and as a speaker for Pfizer and Roche.

Address correspondence to: Vinod Yalamanchili, MBBS, Bone Metabolism Unit, Creighton University School of Medicine, 601 North 30th Street, Suite 6718, Omaha, NE 68131. E-mail: vinod@creighton.edu

©2012The North American Menopause Society